News

MOTS-c vs GLP-1: FDA Regulatory Pathways and Approval Timelines
MOTS-c and GLP-1 drugs follow divergent FDA regulatory pathways. GLP-1 agonists achieved approval through established mechanisms; MOTS-c remains in research phase without IND status. Read more...
AOD-9604 vs GLP-1: Regulatory Status and Bone Safety in Weight Loss
AOD-9604 and GLP-1 drugs differ sharply in regulatory status and bone safety evidence. GLP-1 drugs are approved but carry documented fracture risk. AOD-9604 remains unproven and unmonitored. Read more...